Glypican-3 (GPC-3) is a cell surface-bound oncofetal proteoglycan which has been identified as a potential prognostic factor and immunotherapeutic target in hepatocellular carcinoma (HCC) [1], lung carcinoma, severe pneumonia, and acute respiratory distress syndrome (ARDS) [2]. This evidence concerns the gene GPC3 and lung carcinoma.